Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 29, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Optimal prostate-specific antigen screening interval for prostate cancer.

D Kobayashi¹, O Takahashi², T Fukui²

¹Department of Medicine, Division of General Internal Medicine, St Luke's International Hospital, Tokyo.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|September 28, 2011

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relationship between blood culture time to positivity, mortality rate, and severity of bacteremia.

Infectious diseases now·2023

Same author

Observation of Single-Top-Quark Production in Association with a Photon Using the ATLAS Detector.

Physical review letters·2023

Same author

Observation of the γγ→ττ Process in Pb+Pb Collisions and Constraints on the τ-Lepton Anomalous Magnetic Moment with the ATLAS Detector.

Physical review letters·2023

Same author

Strong Constraints on Jet Quenching in Centrality-Dependent p+Pb Collisions at 5.02 TeV from ATLAS.

Physical review letters·2023

Same author

Search for Heavy Neutral Leptons in Decays of W Bosons Using a Dilepton Displaced Vertex in sqrt[s]=13 TeV pp Collisions with the ATLAS Detector.

Physical review letters·2023

Same author

Test of CP Invariance in Higgs Boson Vector-Boson-Fusion Production Using the H→γγ Channel with the ATLAS Detector.

Physical review letters·2023

For men over 50, repeat prostate-specific antigen (PSA) screening intervals depend on baseline levels. Men with PSA 3.0-3.9 ng/ml should be rescreened in 2 years; others can wait 3+ years. PSA screening is not recommended for men under 50.

Area of Science:

Urology
Preventive Medicine
Oncology

Background:

Prostate cancer screening guidelines often lack specific recommendations for repeat prostate-specific antigen (PSA) testing intervals.
Determining optimal PSA testing frequency is crucial for early detection while minimizing overdiagnosis and overtreatment.

Purpose of the Study:

To identify the optimal interval for repeat prostate-specific antigen (PSA) testing in healthy adult males for prostate cancer screening.

Main Methods:

A retrospective cohort study analyzed 7332 healthy males from 2005-2008 undergoing annual PSA testing.
Subgroup analysis was performed based on age (<50 and ≥50 years) and baseline PSA levels (≥4.0 ng/ml triggered further examination).

Main Results:

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Experiment Videos

Last Updated: May 29, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

In men ≥50 years, 3-year cumulative prostate cancer incidence varied by baseline PSA: 0% (<1.0 ng/ml), 0.1% (1.0-1.9 ng/ml), 0.3% (2.0-2.9 ng/ml), and 5.7% (3.0-3.9 ng/ml).

No prostate cancer was detected in men <50 years, irrespective of baseline PSA levels.

Conclusions:

For men >50 years with baseline PSA 3.0-3.9 ng/ml, a 2-year rescreening interval is suggested.
Men >50 years with PSA <3.0 ng/ml may have appropriate rescreening intervals of 3 years or longer.
PSA screening appears unnecessary for men <50 years of age.